Clinical Trials Directory

Trials / Conditions / Relapsed/Refractory Diffuse Large B-cell Lymphoma

Relapsed/Refractory Diffuse Large B-cell Lymphoma

13 registered clinical trials studyying Relapsed/Refractory Diffuse Large B-cell Lymphoma — 5 currently recruiting.

StatusTrialSponsorPhase
RecruitingSafety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
NCT06902012
Zhujiang HospitalPhase 1 / Phase 2
RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT07409428
HutchmedPhase 3
RecruitingLow Dose Epcoritamab Plus GemOx in R/R DLBCL
NCT07451652
Hospital Universitario Dr. Jose E. GonzalezPhase 2
RecruitingStudy Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell
NCT06792253
BeBetter Med IncPhase 3
Active Not RecruitingStudy of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
NCT06601504
HutchmedPhase 2
UnknownStudy of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06164327
BeBetter Med IncPhase 1
TerminatedNKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Ly
NCT05664217
Nektar TherapeuticsPhase 2 / Phase 3
Active Not RecruitingGPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma
NCT05335018
Seoul National University HospitalPhase 2
TerminatedA Study of ATG-010 in Combination With ATG-008 in Patients With Relapsed/Refractory Diffuse Large B-cell Lymph
NCT05354362
Antengene CorporationPhase 1
CompletedZanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refrac
NCT04436107
BeiGenePhase 1
RecruitingA Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Rel
NCT04442022
Karyopharm Therapeutics IncPhase 2 / Phase 3
CompletedA Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
NCT03886831
Prelude TherapeuticsPhase 1
Approved For MarketingAxicabtagene Ciloleucel Expanded Access Study
NCT03153462
Kite, A Gilead Company—